Hepatopancreatobiliary Carcinoma — Trials

Hepatopancreatobiliary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,361
Recruiting: 790
Ph III recruiting: 74
Growth YoY: +9.6%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (646)

clinicaltrialsPublishedShowing 101–150 of 681 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02867592	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	active not recruiting	Phase 2	109	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT07632235	A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma	not yet recruiting	Phase 1 / Phase 2	112	Shanghai 6th People's Hospital